Medindia LOGIN REGISTER
Medindia

Prognosis of Interval Breast Cancer

by Anne Trueman on Dec 24 2012 1:00 PM
Listen to this article
0:00/0:00

According to researchers, the prognosis of interval breast cancer and cancer detected in the absence of regular mammography are similar.

Breast cancer is a common cancer among women and accounts for loss of valuable lives every year. Regular screening for breast cancer is done with the help of mammograms.  However, in some cases, the cancer is diagnosed or identified after a negative mammogram and before the next scheduled mammogram; these cancers are referred to as interval breast cancers.  Some suggest that these tumors should be treated more aggressively.

Mette Kalager and colleagues conducted a study to assess the prognosis of women with interval breast cancer. The study was published in BMJ 2012. It was carried out in Norway in the period between 1996 and 2005

The researchers enrolled 7116 females in the age group of 50 to 72 years, with a diagnosis breast cancer. 5300 women patients were diagnosed with breast cancer  who had not undergone proper screening, while 1816 patients were identified with interval breast cancer.

The patients were followed for 10 years and it was noted that the rate of survival among interval breast cancer patients was 79.1 percent and among non-screened cancer patients was 76.8 percent.   

The scientists said that ‘tumors associated with interval breast cancers are more likely to be larger than those diagnosed in the absence of mammography screening; but they have strikingly similar survival outcomes.’

They concluded that both non-screened breast cancer females and those with interval breast cancer had almost identical prognosis of breast cancer with no significant variation.  It is therefore not necessary to treat interval tumors more aggressively as compared to non-screened breast cancers.

Advertisement
Reference:

Prognosis in women with interval breast cancer: population based observational cohort study; Mette Kalager et al; BMJ 2012

Advertisement
Source-Medindia


Advertisement